Consensos, recomendaciones, guías y perspectivas

Contexto: la pasireotida ha demostrado eficacia en el tratamiento de pacientes con enfermedad de Cushing y acromegalia; sin embargo, es frecuente que los pacientes tratados con pasireotida presenten hiperglucemia.

Objetivo: proporcionar lineamientos y recomendaciones en Colombia para el control y el manejo de hiperglucemia secundaria a pasireotida en pacientes con enfermedad de Cushing y acromegalia.

Metodología: se utilizó la metodología de panel de expertos. Previo al panel se hizo una revisión de la evidencia disponible para las preguntas de interés formuladas por especialistas en Endocrinología, la cual fue actualizada posterior a la reunión. Participaron especialistas de diferentes zonas del país, quienes discutieron las preguntas y formularon recomendaciones para el control y el tratamiento de la hiperglucemia secundaria a pasireotida en enfermedad de Cushing y acromegalia.

Resultados: se formularon 16 recomendaciones para el control y manejo de la hiperglucemia secundaria al uso de pasireotida en pacientes con enfermedad de Cushing y 7 para pacientes con acromegalia. Las recomendaciones fueron formuladas y validadas por un panel de expertos, a partir de evidencia y de su experiencia clínica.

Conclusiones: es frecuente que pacientes con acromegalia o enfermedad de Cushing tratados con pasireotida presenten alteraciones en el metabolismo de la glucosa como consecuencia de la terapia. Existe poca evidencia de alto nivel para la formulación de recomendaciones para el manejo de la hiperglucemia secundaria al uso de pasireotida en ambas patologías, aquí las recomendaciones generadas fueron con base en opinión de expertos y son las primeras publicadas para Colombia.

Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, et al. A 12-Month Phase 3 Study of Pasireotide in Cushing’s Disease. N Engl J Med. 2012;366(10):914–24.

Colao A, Boscaro M, Ferone D, Casanueva FF. Managing Cushing ’ s disease?: the state of the art. Endocrine. 2014;47:9–20.

Fleseriu M, Cuevas-Ramos D. Pasireotide: a novel treatment for patients with acromegaly. Drug Des Devel Ther. 2016;227.

Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M, et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): A randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2(11):875–84.

Castellanos-Bueno R, Abreu-Lomba A, Buitrago-Gómez N, Patiño-Arboleda M, Pantoja-Guerrero D, Valenzuela-Rincón A, et al. Clinical and epidemiological characteristics, morbidity and treatment based on the registry of acromegalic patients in Colombia: RAPACO. Growth Horm IGF Res [Internet]. 2021 Oct;60–61(101425):101425. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1096637421000484

Ceballos-delgado Y, Carvajal R, Buitrago-gómez N, Delgado A, Rivera A, Osorio V, et al. Efectividad de la terapia con análogos de somatostatina sobre el control de pacientes con acromegalia no curados con tratamiento quirúrgico en un centro de alta complejidad. Rev Colomb Endocrinol Diabetes Metab [Internet]. 2021;8(1):1–12. Available from: https://doi.org/10.53853/encr.8.1.661

Henry RR, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M, Mudaliar S. Hyperglycemia associated with pasireotide: Results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab. 2013;98(8):3446–53.

Kumar U, Sasi R, Suresh S, Patel A, Thangaraju M, Metrakos P, et al. Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. Diabetes. 1999 Jan;48(1):77–85.

Ceccato F, Scaroni C, Boscaro M. Clinical use of pasireotide for Cushing ’ s disease in adults. Ther Clin risk mangement. 2015;11:425–34.

Silverstein JM. Hyperglycemia induced by pasireotide in patients with Cushing’s disease or acromegaly. Pituitary. 2016;19(5):536–43.

Reznik Y, Bertherat J, Borson-chazot F, Brue T, Chanson P, Cortet-rudelli C. Management of hyperglycaemia in Cushing ’ s disease?: Experts ’ proposals on the use of pasireotide. Diabetes Metab. 2013;39(1):34–41.

Colao A, Block C De, Sonia M, Sudhesh G, Seufert J, Casanueva FF. Managing hyperglycemia in patients with Cushing ’ s disease treated with pasireotide?: medical expert recommendations. Pituitary. 2014;17:180–6.

Lindholm J, Juul S, Jørgensen JOL, Astrup J, Bjerre P, Feldt-Rasmussen U, et al. Incidence and Late Prognosis of Cushing’s Syndrome: A Population-Based Study 1. J Clin Endocrinol Metab. 2001 Jan;86(1):117–23.

Etxabe J, Vazquez JA. Morbidity and mortality in Cushing’s disease: an epidemiological approach. Clin Endocrinol (Oxf). 1994 Apr;40(4):479–84.

García JMM. Hipercortisolismo de origen suprarrenal?: síndrome de Cushing. Medicine (Baltimore). 2008;10(15):967–75.

Bertagna X, Guignat L, Groussin L. Cushing ’ s disease. Best Pract Res Clin Endocrinol Metab. 2009;23:607–23.

Feelders RA, Pulgar SJ, Kempel A, Pereira AM. The burden of Cushing’s disease: Clinical and health-related quality of life aspects. Eur J Endocrinol. 2012;167(3):311–26.

Ferrau F. Metabolic comorbidities in Cushing ’ s syndrome. Eur J Endocrinol. 2015;173:M133–57.

Faggiano A, Pivonello R, Spiezia S, De Martino MC, Filippella M, Di Somma C, et al. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing’s disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab. 2003 Jun;88(6):2527–33.

Mancini T, Kola B, Mantero F, Boscaro M, Arnaldi G. High cardiovascular risk in patients with Cushing’s syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol (Oxf). 2004 Dec;61(6):768–77.

Tauchmanovà L, Rossi R, Biondi B, Pulcrano M, Nuzzo V, Palmieri E-A, et al. Patients with subclinical Cushing’s syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab. 2002 Nov;87(11):4872–8.

Petersenn S. How to manage pasireotide, when using as medical treatment for Cushing’s disease. Endocrine. 2015;50(3):526–8.

Mazziotti G, Gazzaruso C, Giustina A. Diabetes in Cushing syndrome?: basic and clinical aspects. Trends Endocrinol Metab. 2011;22(12):499–506.

van Raalte DH, Ouwens DM, Diamant M. Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest. 2009 Feb;39(2):81–93.

Shenouda M, Maldonado M, Wang Y, Bouillaud E, Hudson M, Nesheiwat D, et al. An Open-Label Dose-Escalation Study of Once-Daily and Twice-Daily Pasireotide in Healthy Volunteers. Am J Ther. 2014;21(3):164–73.

Ministerio de Salud y Protección Social de Colombia. pospopuli. 2016.

Breitschaft A, Hu K, Hermosillo Res??ndiz K, Darstein C, Golor G. Management of hyperglycemia associated with pasireotide (SOM230): Healthy volunteer study. Diabetes Res Clin Pract. 2014;103(3):458–65.

Scacchi M, Cavagnini F. Acromegaly. Pituitary. 2006;9(4):297-303.

Katznelson L, Laws ER, Melmed S, Molitch ME, Murad MH, Utz A, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014 Dec;99(11):3933–51.

Abu Dabrh AM, Mohammed K, Asi N, Farah WH, Wang Z, Farah MH, et al. Surgical interventions and medical treatments in treatment-naïve patients with acromegaly: systematic review and meta-analysis. J Clin Endocrinol Metab. 2014 Nov;99(11):4003–14.

Ntali G, Karavitaki N. Recent advances in the management of acromegaly [version 1; referees: 2 approved] F1000Research 2015, 4(F1000 Faculty Rev):1426 (doi: 10.12688/f1000research.7043.1).

Giustina A, Chanson P, Kleinberg D, Bronstein MD, Clemmons DR, Klibanski A, et al. Expert consensus document: A consensus on the medical treatment of acromegaly. Nat Rev Endocrinol. 2014;10(4):243–8.

Cordido F, García Arnés JA, Marazuela Aspiroz M, Torres Vela E. Guía práctica de diagnóstico y tratamiento de la acromegalia. Endocrinol y Nutr. 2013;60(8):457.e1-457.e15.

Chih Hao C-K. Guías para el diagnóstico y tratamiento de acromegalia, prolactinomas y enfermedad de Cushing. Acta Med Costarric. 2004;46:25–36.

Arosio M, Reimondo G, Malchiodi E, Berchialla P, Borraccino A, De Marinis L, et al. Predictors of morbidity and mortality in acromegaly: An Italian survey. Eur J Endocrinol. 2012;167(2):189–98.

Colao A, Bronstein MD, Freda P, Gu F, Shen C-C, Gadelha M, et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab. 2014 Mar;99(3):791–9.

Møller N, Jørgensen JOL. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 2009 Apr;30(2):152–77.

Alexopoulou O, Bex M, Kamenicky P, Mvoula AB, Chanson P, Maiter D. Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients. Pituitary. 2014 Feb;17(1):81–9.

Dreval a V, Trigolosova I V, Misnikova I V, Kovalyova Y a, Tishenina RS, Barsukov I a, et al. Prevalence of diabetes mellitus in patients with acromegaly. Endocr Connect. 2014;3(2):93–8.

Espinosa-de-los-Monteros AL, González B, Vargas G, Sosa E, Mercado M. Clinical and biochemical characteristics of acromegalic patients with different abnormalities in glucose metabolism. Pituitary. 2011 Sep;14(3):231–5.

Kreze A, Kreze-Spirova E, Mikulecky M. Risk factors for glucose intolerance in active acromegaly. Brazilian J Med Biol Res = Rev Bras Pesqui me?dicas e biolo?gicas / Soc Bras Biofi?sica . [et al]. 2001 Nov;34(11):1429–33.

Fieffe S, Morange I, Petrossians P, Chanson P, Rohmer V, Cortet C, et al. Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry. Eur J Endocrinol. 2011 Jun;164(6):877–84.

Møller N, Schmitz O, Jøorgensen J, Astrup J, Bak J, Christensen S, et al. Basal- and insulin-stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy: Vol 74, No 5. J Clin Endocrinol Metab. 1992;74(5):1012–9.

Kasayama S, Otsuki M, Takagi M, Saito H, Sumitani S, Kouhara H, et al. Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol (Oxf). 2000 May;52(5):549–55.

Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A. Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab. 2009 May;94(5):1500–8.

Baroni MG, Giorgino F, Pezzino V, Scaroni C, Avogaro A. Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing’s syndrome and acromegaly. J Endocrinol Invest. 2015;39(2):235–55.

Cambuli VM, Galdiero M, Mastinu M, Pigliaru F, Auriemma RS, Ciresi A, et al. Glycometabolic control in acromegalic patients with diabetes: A study of the effects of different treatments for growth hormone excess and for hyperglycemia. J Endocrinol Invest. 2012;35(2):154–9.

Samson SL. Management of Hyperglycemia in Patients With Acromegaly Treated With Pasireotide LAR. Drugs. 2016;76(13):1235–43.

Samson SL, Gu F, Feldt-Rasmussen U, Zhang S, Yu Y, Witek P, et al. Managing pasireotide-associated hyperglycemia: a randomized, open-label, Phase IV study. Pituitary [Internet]. 2021;24(6):887–903. Available from: https://doi.org/10.1007/s11102-021-01161-4

Enfermedad de Cushing
Acromegalia
Hiperglucemia
Pasireotide